atypical antipsychotics (68 resultados)

Audio Book (CD). Condición: Very Good. CD 2009 edition in sleeve. Atypical Antipsychotics in Children and Adolescents: Balancing Safety and Efficacy. Volume 55, Issue 16, August 21, 2009. CD in very good condition.

Condición: As New. Unread book in perfect condition.

Condición: As New. Unread book in perfect condition.

Condición: As New. Unread book in perfect condition.

Condición: New. pp. ix + 342 1st Edition.

Condición: New.

Condición: As New. Unread book in perfect condition.

Condición: New. pp. ix + 342.

Condición: Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service.

Condición: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide.

Condición: New. Brand New Original US Edition. Customer service! Satisfaction Guaranteed.

Condición: New.

Condición: New. Brand New Original US Edition. Customer service! Satisfaction Guaranteed.

Condición: New.

Condición: New.

Condición: As New. Unread book in perfect condition.

8vo, 23.3cm. Pp. xii,236, refs. & notes, index. Hardbound, orig. printed boards. Name to front end-paper, fine otherwise, as new.

Condición: New.

Condición: New. Brand New ! Fast Delivery "International Edition " and ship within 24-48 hours. Deliver by FedEx and Dhl, & Aramex, UPS, & USPS and we do accept APO and PO BOX Addresses. Order can be delivered worldwide within 4-6 Working days .and we do have flat rate for up to 2LB. Extra shipping charges will be requested This Item May be shipped from India, United states & United Kingdom. Depending on your location and availability.

Paperback. Condición: new. Paperback. Antipsychotics medications are approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia and bipolar disorder. These medications are commonly divided into two classes, reflecting two waves of historical development: the conventional antipsychotics and the atypical. The conventional antipsychotics served as the first successful pharmacologic treatment for primary psychotic disorders such as schizophrenia. Having been widely used for decades, the conventional antipsychotics also produced various side effects requiring additional medications, which spurred the development of the atypical antipsychotics. Currently, nine atypical antipsychotic drugs have been approved by FDA: aripiprazole, asenapine, clozapine, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone. These drugs have been used off-label for the treatment of various psychiatric conditions. A 2006 study on Efficacy and Comparative Effectiveness of Off-label Use of Atypical Antipsychotics reviewed the scientific evidence on the safety, efficacy, and effectiveness for off-label uses. (Clozapine was excluded because of its association with a potentially fatal blood disorder of bone marrow suppression, and it requires frequent blood tests for safety monitoring.) The 2006 study examined 84 published studies on atypicals and found that the most common off-label uses of the drugs were for treatment of depression, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), personality disorders, Tourette's syndrome, autism, and agitation in dementia. It concluded that with few exceptions, there was insufficient high-strength evidence to reach conclusions about the efficacy of any off-label uses of these medications. It also found strong evidence that atypicals are associated with increased risk of adverse events such as significant weight gain, sedation, and, among the elderly, increased mortality. Future research areas suggested by the report include safe treatment for agitation in dementia, association between the increased risk of death and antipsychotics drugs, and comparison of the development of adverse effects between patients taking atypical antipsychotics and those taking conventional antipsychotics. Since publication of that report, important changes have occurred that make the report out of date. New or increased adverse effects of off-label indications have been observed and new atypicals (asenapine, iloperidone, and paliperidone) have been approved by FDA for the treatment of schizophrenia and bipolar disorder. This report covers the following off-label uses of atypical antipsychotic medications: anxiety, ADHD, dementia and severe geriatric agitation, major depressive disorder (MDD), eating disorders, insomnia, OCD, PTSD, personality disorders, substance abuse, and Tourette's syndrome. This report addresses the following Key Questions: KQ1. What are the leading off-label uses of atypical antipsychotics in utilization studies? How have trends in utilization changed in recent years, including inpatient versus outpatient use? What new uses are being studied in trials? KQ2. What does the evidence show regarding the efficacy and comparative effectiveness of atypical antipsychotics for off-label indications? Sub-KQ 2. How do atypical antipsychotic medications compare with other drugs, including first-generation antipsychotics, for treating off-label indications? KQ3. What subset of the population would potentially benefit from off-label uses? Do effectiveness and harms differ by race/ethnicity, gender, and age group? By severity of condition and clinical subtype? KQ4. What are the potential adverse effects and/or complications involved with off label prescribing of atypical antipsychotics? How do they compare within the class and with other drugs used for the conditions? KQ5. What Shipping may be from our UK warehouse or from our Australian or US warehouses, depending on stock availability.

Condición: As New. Unread book in perfect condition.

Condición: New.

Taschenbuch. Condición: Neu. Typical and Atypical Antipsychotics among Schizophrenic Patients | A Comparative Study on Neurocognitive effects ofTypical and Atypical Antipsychotics amongSchizophrenic Patients | Venkatewara Rao Jallepalli (u. a.) | Taschenbuch | Englisch | 2022 | LAP LAMBERT Academic Publishing | EAN 9786205488188 | Verantwortliche Person für die EU: preigu GmbH & Co. KG, Lengericher Landstr. 19, 49078 Osnabrück, mail[at]preigu[dot]de | Anbieter: preigu.

Taschenbuch. Condición: Neu. Adverse Metabolic Effects of Conventional and Atypical Antipsychotics | Changes in Blood Glucose, Serum Cholesterol, BMI with Haloperidol, Risperidone and Olanzapine | Najam Akhtar (u. a.) | Taschenbuch | Englisch | LAP Lambert Academic Publishing | EAN 9783659249082 | Verantwortliche Person für die EU: preigu GmbH & Co. KG, Lengericher Landstr. 19, 49078 Osnabrück, mail[at]preigu[dot]de | Anbieter: preigu.

Condición: Sehr gut. Zustand: Sehr gut | Sprache: Englisch | Produktart: Bücher | Source: Wikipedia. Pages: 61. Chapters: Atypical antipsychotics, Azapirones, Tardive dyskinesia, Typical antipsychotics, Neuroleptic malignant syndrome, Clozapine, Olanzapine, Quetiapine, Lithium, Aripiprazole, Diphenhydramine, Cannabidiol, Risperidone, Ziprasidone, Thioridazine, Clocapramine, Buspirone, Iloperidone, Sulpiride, Amisulpride, Tandospirone, Lurasidone, Tiospirone, Piquindone, Asenapine, Sertindole, Eptapirone, Paliperidone, Desmethylclozapine, Tetrabenazine, Benzatropine, Olanzapine/fluoxetine, Vabicaserin, Blonanserin, GTS-21, Loxapine, List of psychotropic medications, Gevotroline, Perospirone, Umespirone, Bifeprunox, Pimavanserin, NMDA receptor modulator, Azacyclonol, Carpipramine, Extrapyramidal symptoms, Molindone, Fluotracen, Zotepine, Remoxipride, Fananserin, Raclopride, Alnespirone, Hematoporphyrin, Procyclidine, Osanetant, Gepirone, Paliperidone palmitate, Benzquinamide, Metergoline, Lunsers, Carphenazine, Ipsapirone, Mosapramine, Ciclindole, Zalospirone, Talnetant, Binospirone, Revospirone, Metitepine, Clotiapine, Enilospirone, Cariprazine, Flucindole, Naranol, Piperacetazine, Pipotiazine, Butaclamol, TC-5619, Flupentixol/melitracen, Chemical cosh, Azaspirodecanedione, Eglonyl, DHA-clozapine. Excerpt: An antipsychotic (or neuroleptic) is a tranquilizing psychiatric medication primarily used to manage psychosis (including delusions or hallucinations, as well as disordered thought), particularly in schizophrenia and bipolar disorder. A first generation of antipsychotics, known as typical antipsychotics, was discovered in the 1950s. Most of the drugs in the second generation, known as atypical antipsychotics, have been developed more recently, although the first atypical antipsychotic, clozapine, was discovered in the 1950s and introduced clinically in the 1970s. Both generations of medication tend to block receptors in the brain's dopamine pathways, but antipsychotic drugs encompass a wide range of receptor targets. A number of harmful and undesired (adverse) effects have been observed, including lowered life expectancy, weight gain, decrease in brain volume, enlarged breasts and milk discharge in men and women (hyperprolactinaemia), lowered white blood cell count (agranulocytosis), involuntary repetitive body movements (tardive dyskinesia), diabetes, an inability to sit still or remain motionless (akathisia), sexual dysfunction, a return of psychosis requiring increasing the dosage due to cells producing more neurochemicals to compensate for the drugs (tardive psychosis), and a potential for permanent chemical dependence leading to psychosis much worse than before treatment began, if the drug dosage is ever lowered or stopped (tardive dysphrenia). Temporary withdrawal symptoms including insomnia, agitation, psychosis, and motor disorders may occur during dosage reduction of antipsychotics, and can be mistaken for a return of the underlying condition. The development of new antipsychotics with fewer of these adverse effects and with greater relative effectiveness as compared to existing antipsychotics (efficacy), is an ongoing field of research. The original antipsychotic drugs were happened upon largely by chance and then tested for their effectiveness. The first,

Condición: Hervorragend. Zustand: Hervorragend | Sprache: Englisch | Produktart: Bücher | Source: Wikipedia. Pages: 61. Chapters: Atypical antipsychotics, Azapirones, Tardive dyskinesia, Typical antipsychotics, Neuroleptic malignant syndrome, Clozapine, Olanzapine, Quetiapine, Lithium, Aripiprazole, Diphenhydramine, Cannabidiol, Risperidone, Ziprasidone, Thioridazine, Clocapramine, Buspirone, Iloperidone, Sulpiride, Amisulpride, Tandospirone, Lurasidone, Tiospirone, Piquindone, Asenapine, Sertindole, Eptapirone, Paliperidone, Desmethylclozapine, Tetrabenazine, Benzatropine, Olanzapine/fluoxetine, Vabicaserin, Blonanserin, GTS-21, Loxapine, List of psychotropic medications, Gevotroline, Perospirone, Umespirone, Bifeprunox, Pimavanserin, NMDA receptor modulator, Azacyclonol, Carpipramine, Extrapyramidal symptoms, Molindone, Fluotracen, Zotepine, Remoxipride, Fananserin, Raclopride, Alnespirone, Hematoporphyrin, Procyclidine, Osanetant, Gepirone, Paliperidone palmitate, Benzquinamide, Metergoline, Lunsers, Carphenazine, Ipsapirone, Mosapramine, Ciclindole, Zalospirone, Talnetant, Binospirone, Revospirone, Metitepine, Clotiapine, Enilospirone, Cariprazine, Flucindole, Naranol, Piperacetazine, Pipotiazine, Butaclamol, TC-5619, Flupentixol/melitracen, Chemical cosh, Azaspirodecanedione, Eglonyl, DHA-clozapine. Excerpt: An antipsychotic (or neuroleptic) is a tranquilizing psychiatric medication primarily used to manage psychosis (including delusions or hallucinations, as well as disordered thought), particularly in schizophrenia and bipolar disorder. A first generation of antipsychotics, known as typical antipsychotics, was discovered in the 1950s. Most of the drugs in the second generation, known as atypical antipsychotics, have been developed more recently, although the first atypical antipsychotic, clozapine, was discovered in the 1950s and introduced clinically in the 1970s. Both generations of medication tend to block receptors in the brain's dopamine pathways, but antipsychotic drugs encompass a wide range of receptor targets. A number of harmful and undesired (adverse) effects have been observed, including lowered life expectancy, weight gain, decrease in brain volume, enlarged breasts and milk discharge in men and women (hyperprolactinaemia), lowered white blood cell count (agranulocytosis), involuntary repetitive body movements (tardive dyskinesia), diabetes, an inability to sit still or remain motionless (akathisia), sexual dysfunction, a return of psychosis requiring increasing the dosage due to cells producing more neurochemicals to compensate for the drugs (tardive psychosis), and a potential for permanent chemical dependence leading to psychosis much worse than before treatment began, if the drug dosage is ever lowered or stopped (tardive dysphrenia). Temporary withdrawal symptoms including insomnia, agitation, psychosis, and motor disorders may occur during dosage reduction of antipsychotics, and can be mistaken for a return of the underlying condition. The development of new antipsychotics with fewer of these adverse effects and with greater relative effectiveness as compared to existing antipsychotics (efficacy), is an ongoing field of research. The original antipsychotic drugs were happened upon largely by chance and then tested for their effectiveness. The first,

Taschenbuch. Condición: Neu. Antipsychotic Induced Metabolic Syndrome | drug emergent metabolic syndrome in schizophrenic patients recieving atypical antipsychotics | Parth Singh Meena | Taschenbuch | Englisch | LAP Lambert Academic Publishing | EAN 9783659002137 | Verantwortliche Person für die EU: preigu GmbH & Co. KG, Lengericher Landstr. 19, 49078 Osnabrück, mail[at]preigu[dot]de | Anbieter: preigu.

Condición: Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service.

Condición: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide.

Paperback. Condición: Like New. LIKE NEW. SHIPS FROM MULTIPLE LOCATIONS. book.